Tularemia, also known as rabbit fever, is a severe zoonotic disease in humans caused by the gram-negative bacterium Francisella tularensis (Ft). While there have been a number of attempts to develop a vaccine for Ft, few candidates have advanced beyond experiments in inbred mice. We report here that a prime-boost strategy with aerosol delivery of recombinant live attenuated candidate Ft S4ΔaroD offers significant protection (83% survival) in an outbred animal model, New Zealand White rabbits, against aerosol challenge with 248 cfu (11 LD50) of virulent type A Ft SCHU S4. Surviving rabbits given two doses of the attenuated strains by aerosol did not exhibit substantial post-challenge fevers, changes in erythrocyte sedimentation rate or in complete blood counts. At a higher challenge dose (3,186 cfu; 139 LD50), protection was still good with 66% of S4ΔaroD-vaccinated rabbits surviving while 50% of S4ΔguaBA vaccinated rabbits also survived challenge. Pre-challenge plasma IgG titers against Ft SCHU S4 corresponded with survival time after challenge. Western blot analysis found that plasma antibody shifted from predominantly targeting Ft O-antigen after the prime vaccination to other antigens after the boost. These results demonstrate the superior protection conferred by a live attenuated derivative of virulent F. tularensis, particularly when given in an aerosol prime-boost regimen.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197691PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205928PLOS

Publication Analysis

Top Keywords

aerosol prime-boost
8
virulent type
8
francisella tularensis
8
live attenuated
8
aerosol
5
rabbits
5
prime-boost vaccination
4
vaccination strong
4
protection
4
strong protection
4

Similar Publications

Early introduction of IL-10 weakens BCG revaccination's protection by suppressing CD4Th1 cell responses.

J Transl Med

December 2024

Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Hubei Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, Huazhong University of Science and Technology, Wuhan, China.

Article Synopsis
  • The BCG vaccine, the only current vaccine for tuberculosis (TB), shows limited effectiveness in protecting adolescents and adults from active TB, which highlights the need for better understanding of its mechanisms and potential improvements.
  • A study conducted on C57BL/6J mice evaluated the effects of BCG vaccination, particularly analyzing cytokine changes, IL-10 expression across various organs, and the immune response following booster doses.
  • Results indicated that IL-10 levels increased significantly in the lungs and other organs after revaccination, and blocking IL-10 signaling led to enhanced immune responses, suggesting that targeting IL-10 could improve the vaccine's effectiveness against TB.
View Article and Find Full Text PDF

Tuberculosis, caused by ( ), remains a leading infectious cause of mortality worldwide despite widespread use of the BCG vaccine and the availability of sterilizing pharmacopoeia. Recent research indicates that the intravenous administration of BCG confers sterilizing immunity against pulmonary challenge in non-human primates. However, while BCG is relatively safe, complications such as disseminated BCGosis have been observed in immunocompromised individuals.

View Article and Find Full Text PDF

The outbreak of coronavirus disease 19 (COVID-19) has highlighted the demand for vaccines that are safe and effective in inducing systemic and airway mucosal immunity against the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we developed a novel helper-dependent adenoviral vector-based COVID-19 mucosal vaccine encoding a full-length SARS-CoV-2 spike protein (HD-Ad-FS). Through intranasal immunization (single-dose and prime-boost regimens), we demonstrated that the HD-Ad-FS was immunogenic and elicited potent systemic and airway mucosal protection in BALB/c mice, transgenic ACE2 (hACE2) mice, and hamsters.

View Article and Find Full Text PDF
Article Synopsis
  • Plague is caused by a bacterium and can show up as different types of disease; antibiotics are essential for treatment, but there's no FDA-approved vaccine yet, and some candidates may work better for certain forms of the disease.
  • The study tested new vaccine approaches on male and female mice and found that the best regimen involved an initial vaccination followed by a boost, with notable differences in effectiveness between sexes.
  • Results showed that female mice had better protection and immune responses compared to males, who also showed higher bacterial loads and different immune reactions, highlighting the importance of understanding sex differences in vaccine development.
View Article and Find Full Text PDF

Inhaled aerosol viral-vectored vaccines against tuberculosis.

Curr Opin Virol

June 2024

The Jenner Institute, Old Road Roosevelt Drive, Oxford OX3 7DQ, UK. Electronic address:

Bacille Calmette-Guérin (BCG) remains the sole licensed vaccine against tuberculosis (TB), despite its variable efficacy in protecting against pulmonary TB. The development of effective TB vaccines faces significant challenges, marked by the absence of validated correlates of protection and predictive animal models. Strategic approaches to enhance TB vaccines and augment BCG efficacy include utilising prime-boost strategies with viral-vectored vaccines and exploring innovative delivery techniques, such as mucosal vaccine administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!